Zoledronic acid prevents fractures in men with osteoporosisBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e7471 (Published 06 November 2012) Cite this as: BMJ 2012;345:e7471
Zoledronic acid, a bisphosphonate given intravenously at a dose of 5 mg once a year, may reduce the risk of morphometric vertebral fractures in men by 67% compared with placebo. Morphometric fractures are identified by a change in shape of a bone, rather than from pain or other symptoms. About 40% of osteoporotic fractures in people over …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial